Where Does Wall Street Think Inovio Pharmaceuticals Inc (INO) Stock Will Go?

InvestorsObserver is giving Inovio Pharmaceuticals Inc (INO) an Analyst Rating Rank of 16, meaning INO is ranked higher by analysts than 16% of stocks. The average price target for INO is $11 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating INO a Buy today. Find out what this means to you and get the rest of the rankings on INO!

See Full INO Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Inovio Pharmaceuticals Inc Stock Today?

Inovio Pharmaceuticals Inc (INO) stock is lower by -4.53% while the S&P 500 has gained 0.29% as of 10:47 AM on Monday, Apr 18. INO is down -$0.14 from the previous closing price of $3.20 on volume of 720,842 shares. Over the past year the S&P 500 has risen 5.81% while INO is down -65.27%. INO lost -$1.45 per share the over the last 12 months. Click Here to get the full Stock Report for Inovio Pharmaceuticals Inc stock.